Edition:
United States

Bristol-Myers Squibb Co (BMYMP.PK)

BMYMP.PK on OTC Markets Group

940.00USD
--
Change (% chg)

-- (--)
Prev Close
$940.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
22
52-wk High
$1,231.90
52-wk Low
$788.70

Select another date:

Sat, Apr 22 2017

Bristol-Myers NASH drug reduces liver fat in midstage study

Bristol-Myers Squibb Co said its lead experimental drug for nonalcoholic steatohepatitis, or NASH, significantly reduced liver fat versus placebo, according to data from a mid-stage trial presented at a medical meeting on Saturday.

Bristol-Myers NASH drug reduces liver fat in midstage study

April 22 Bristol-Myers Squibb Co said its lead experimental drug for nonalcoholic steatohepatitis, or NASH, significantly reduced liver fat versus placebo, according to data from a mid-stage trial presented at a medical meeting on Saturday.

BRIEF-Bristol-Myers gets positive CHMP opinion recommending approval of Opdivo for treatment of a type of bladder cancer

* Bristol-Myers Squibb receives positive CHMP opinion recommending approval of Opdivo (Nivolumab) for the treatment of patients with previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer

BRIEF-Bristol-Myers,Nordic Bioscience announce collaboration for fibrosis biomarker technology

* Bristol-Myers Squibb and Nordic Bioscience announce collaboration for fibrosis biomarker technology

Bristol-Myers to license two drugs to Biogen, Roche

Bristol-Myers Squibb Co said on Thursday it would license two of its drugs to Biogen Inc and Roche Holding AG for an upfront fee of $470 million.

UPDATE 2-Bristol-Myers to license two drugs to Biogen, Roche

* Deals come amid activist investor pressure (Adds background on activist investor pressure)

BRIEF-Biogen licenses Phase 2 Anti-Tau antibody from Bristol-Myers Squibb

* Biogen Inc - under agreement, biogen will receive worldwide rights to BMS-986168

Bristol-Myers to license two of its drugs to Biogen, Roche

April 13 Bristol-Myers Squibb Co said on Thursday it entered into a deal with Biogen Inc and Roche Holding AG to license two of its drugs for an upfront fee of $470 million.

BRIEF-Bristol-Myers Squibb enters into separate agreements with Biogen and Roche

* Bristol-Myers Squibb enters into separate agreements with Biogen and Roche to license anti-etau and anti-myostatin compounds, respectively

BRIEF-Bristol-Myers and Apexigen announce clinical collaboration to evaluate Opdivo in combination with APX005M in advanced solid tumors

* Bristol-Myers Squibb and Apexigen, Inc. announce clinical collaboration to evaluate Opdivo (nivolumab) in combination with APX005M in advanced solid tumors

Select another date:

More From Around the Web